Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register studyTorsten Dahlén, Leif Stenke, Gustaf Edgren et al.|American Journal of Hematology|2022Cited by 15
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Johan Richter, Arta Dremaine et al.|British Journal of Haematology|2021Cited by 15
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trialHjalmar Flygt, Ulla Olsson‐Strömberg, Stina Söderlund et al.|Leukemia|2024Cited by 13
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 studyHjalmar Flygt, Henrik Hjorth‐Hansen, Stina Söderlund et al.|European Journal Of Haematology|2021Cited by 10
The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based studyTorsten Dahlén, Fredrik Nyberg, Hjalmar Flygt et al.|Leukemia|2023Cited by 5